Constitutively overactive NF-κB is also common in both solid and hematological cancers (Karin et al., 2002; Imbert and Peyron, 2017), with altered NF-κB expression associated with worse patient outcomes (Wu et al., 2015). Here, NFKB1 is linked to hematopoietic and lymphoid cell neoplasm.